Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Tofacitinib suppresses pro-inflammatory signaling that may be important pathogenetically to progression to more severe lung disease and acute respiratory distress syndrome (ARDS) in patients with COVID-19. The purpose of the study is to assess the safety and efficacy of tofacitinib plus standard pharmacologic and supportive measures in treating hospitalized participants with COVID-19 pneumonia.
Epistemonikos ID: f67ff92748a7ef07d0cef4ba5be853f4a587a8d3
First added on: Jul 14, 2020